R&D Projects

We provide a new treatment in a field of innovative new drugs (NCE & biologics), stem cell therapy and incrementally modified drugs

Introduction of Pipeline

The Daewoong Pharmaceutical R&D center is focusing on research and development in fields with high market demands such as chronic diseases, intractable diseases and improving quality of life to provide innovative new drugs (NCE, biologics), stem cell therapy and incrementally modified drugs for patients.
Innovative
new drugs
Gatroesophageal reflux disease drugs
Diabetes drugs
Fibrosis drugs
Autoimmunity drugs
Chronic pain drugs
Biologics &
Stem Cell Therapy
Dry eye treatment
Immuno-oncology anti-cancer therapy
Stem cell therapy
Incrementally
Modified Drugs (IMD)
Combination Drugs
Extended-Release Drugs
Sustained Release Injectable products

R&D Projects

  1. Research

    • DWJ215 Hearing loss
    • DWJ816S001 Oncology
    • DWJ816S002 Oncology
    • HL186
      Immuno-oncology
    • HL187 Immuno-oncology
    • DWP458 Osteoporosis
    • DWP820S008 Asthma
  2. Pre-clinical

  3. PhaseⅠ

  4. PhaseⅡ

    • DWP305401 Ulcerative colitis
    • DWJ1248 (MFDS/Mexico)COVID-19
    • DWP706 Corneal wound
    • DWP708 ERSE
  5. PhaseⅢ

    • Enavogliflozin Type2 Diabetes
    • HL036 Dry eye syndrome
    • Furestem-CD Crohn’s disease
  6. NDA

Fexuprazan
(NDA)
Gastroesophageal Reflux Disease
Best-in-Class - New drug pipeline being developed with the goal of best new drugs in series
‘Fexuprazan’ is a next-generation drug for gastroesophageal reflux disease with P-CAB mechanism that submitted a drug applcation to the Ministry of Food and Drug Safety (MFDS) after completing domestic phase 3 clinical trials. Fexuprazan is a treatment for gastroesophageal reflux disease that reversibly blocks proton pumps from secreting gastric acid in the stomach.
DWP213388
Autoimmune disease
(rheumatoid arthritis, Psoriasis)
First-in-Class World's First Innovative New Drug Pipeline
‘DWP213388’ is an oral dosage form of another autoimmune disease drug candidate with a mechanism that selectively suppresses ITK (Interleukin-2-inducible T-cell kinase) and BTK (Bruton's tyrosine kinase), which are targets involved in activating immune cells (T cell and B cell). We are striving to develop a leading global drug to treat patients with autoimmune disease (rheumatoid arthritis, Psoriasis) & inflammatory disease in which effective treatment options are insufficient.
DWP16001
SGLT2 Diabetes
Best-in-Class - New drug pipeline being developed with the goal of best new drugs in series
‘DWP16001’ shows better effect and longer duration than existing products through a SGLT-2 suppression mechanism for treatment of type 2 diabetes, and R&D is being conducted with the goal of receiving approval for sales in 2023 by recently beginning Phase 2 clinical trial.
DWP17061
Arthritis Pain
First-in-Class World's First Innovative New Drug Pipeline
‘DWP17061’ is a treatment for chronic pain being developed with indication for arthritis and it blocks Nav1.7, a sodium channel.
DWP212525
Autoimmune disease (Pemphigus, rheumatoid arthritis, inflammatory bowel disease)
First-in-Class World's First Innovative New Drug Pipeline
‘DWP212525’ is an oral dosage form autoimmune disease treatment candidate that selectively suppresses JAK3 and TFK involved in activating cells of the immune system (T cell and B cell). We are currently focusing on research to develop various autoimmune disease treatments for pemphigus for which an effective treatment is yet nonexistent, rheumatic arthritis and inflammatory bowel disease.
DWN12088
Idopathic Pulmonary Fibrosis
First-in-Class - New drug pipeline being developed for the first time in the world
‘DWN12088’ is the first pulmonary fibrosis drug being developed in the world and it is a first-in-class pulmonary fibrosis drug with a new mechanism that suppresses excessive generation of collagen, a cause of pulmonary fibrosis, by reducing the action of Prolyl-tRNA synthetase (PRS) protein. It was selected as a supported project by the pan-government new drug development team in March 2019 and was designated as a orphan drug by the US FDA in August.

Stem cell therapy

DW-MSC [mesenchymal stem cell]

DW-MSC [mesenchymal stem cell] is under development as a drug for intractable and rare diseases and degenerative diseases as well as a genetic delivery platform to strengthen stem cell functions. As a stem cell therapy, DW-MSC is being developed with indications for acute pancreatitis, stroke, dementia, cerebral atrophy, and idiopathic pulmonary fibrosis. ‘DW-MSC’ is the 1st mass production available stem cell line developed in Korea which has a high competitiveness for commercialization. Daewoong aims to develop a best-in-class stem cell therapy by applying Cell & Gene technologies to optimize its functions under the name of “Smart Stem Cell”

Incrementally Modified Drugs (IMD)

Development of incrementally modified drugs based on future-oriented platforms

Daewoong Pharmaceutical is continuously developing new products of 2-in-1, 3-in-1, 4-in-1 combination drugs, multi-delivery sustained release oral forms and long-acting depot injections by using a platform technology (oral dosage forms such as core tablets, multi-layer tablets, multi-filling capsules, and long acting depot injections based on microsphere/nano technology). We, also, are working on life cycle extension of key products that form the brand image of Daewoong Pharmaceutical.